Delivering precision medicines for chronic multifactorial diseases
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.
A paper by the MultiOmic team members was published in the May issue of the ICT magazine
What insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis
In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.
Leveraging deep omics data to tackle a global health challenge with precision
We are excited to announce our feature in the most recent edition of Nature Portfolio’s Biopharma Dealmakers discussing the advances in AI-driven drug development.